Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Thorax. 2018 Aug 3;74(1):43–50. doi: 10.1136/thoraxjnl-2018-211576

Figure 7. Lack of a Therapeutic Effect of MSC MVs on Lung Compliance or Oxygenation following Severe Escherichia coli Pneumonia in Ex Vivo Perfused Human Lung.

Figure 7.

Figure 7.

Figure 7.

Administration of MSC MVs or Poly (I:C) pretreated MSC MVs had no significant effect on tracheal pressure (A), lung compliance (B) or oxygenation (C) over 6 h. Data is presented as median Tracheal pressure or Lung Compliance or PaO2 with IQR as bars. P = 0.56 – 0.98 for each time point by Kruskal Wallis tests (A). P = 0.56 – 0.98 for each time point by Kruskal Wallis tests (B). P = 0.10 – 0.92 for each time point by Kruskal Wallis tests (C).